These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20063113)

  • 21. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.
    Hajder M; Hajder E; Dervisefendic M; Samardzic R; Alic E
    Med Arch; 2013; 67(3):181-4. PubMed ID: 23848038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas.
    Su Z; Wang C; Wu J; Jiang X; Chen Y; Chen Y; Zheng W; Zhuge Q; Wu Z; Zeng Y
    Neurol Sci; 2012 Apr; 33(2):275-9. PubMed ID: 21748460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features and medical treatment of male prolactinomas.
    Asano S; Ueki K; Suzuki I; Kirino T
    Acta Neurochir (Wien); 2001; 143(5):465-70. PubMed ID: 11482696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
    Peverelli E; Mantovani G; Vitali E; Elli FM; Olgiati L; Ferrero S; Laws ER; Della Mina P; Villa A; Beck-Peccoz P; Spada A; Lania AG
    J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk.
    Paez-Pereda M; Giacomini D; Refojo D; Nagashima AC; Hopfner U; Grubler Y; Chervin A; Goldberg V; Goya R; Hentges ST; Low MJ; Holsboer F; Stalla GK; Arzt E
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1034-9. PubMed ID: 12552124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
    Zhang HW; Yu CJ; Sun W; Yang J; Yan CX; Cun EH
    Zhonghua Wai Ke Za Zhi; 2006 Nov; 44(22):1555-7. PubMed ID: 17359664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
    Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
    Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma.
    Gruszka A; Kunert-Radek J; Pawlikowski M
    Folia Histochem Cytobiol; 2004; 42(1):35-9. PubMed ID: 15046398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
    Lloyd HM; Jacobi JM; Willgoss DA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
    Bai J; Gui S; Zhang Y
    J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
    Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
    Shimazu S; Shimatsu A; Yamada S; Inoshita N; Nagamura Y; Usui T; Tsukada T
    Eur J Endocrinol; 2012 Mar; 166(3):383-90. PubMed ID: 22127489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
    Musolino NR; Passos VQ
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of bromocriptine on the treatment of prolactinomas in male patients and its influences on their sexual function].
    Xue XC; Jiang S; Yin SL; Zhong CH; Zhou PZ; Cheng SW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 May; 44(3):452-7. PubMed ID: 23898534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prolactinoma in man: clinical and histological characteristics].
    Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
    Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
    Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.